Orthocell Past Earnings Performance
Past criteria checks 0/6
Orthocell's earnings have been declining at an average annual rate of -5.1%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been growing at an average rate of 40.7% per year.
Key information
-5.1%
Earnings growth rate
5.9%
EPS growth rate
Biotechs Industry Growth | 9.6% |
Revenue growth rate | 40.7% |
Return on equity | -340.7% |
Net Margin | -154.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year
Oct 25We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth
Nov 16We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate
Jul 29Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans
Mar 23We're Not Worried About Orthocell's (ASX:OCC) Cash Burn
Dec 08Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation
May 31Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth
Feb 15How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?
Dec 24Revenue & Expenses BreakdownBeta
How Orthocell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 5 | -7 | 8 | 8 |
30 Sep 23 | 5 | -7 | 7 | 8 |
30 Jun 23 | 4 | -6 | 6 | 8 |
31 Mar 23 | 3 | -7 | 6 | 7 |
31 Dec 22 | 2 | -9 | 6 | 7 |
30 Sep 22 | 2 | -9 | 6 | 7 |
30 Jun 22 | 2 | -9 | 6 | 7 |
31 Mar 22 | 1 | -9 | 5 | 6 |
31 Dec 21 | 1 | -9 | 4 | 6 |
30 Sep 21 | 1 | -9 | 4 | 7 |
30 Jun 21 | 1 | -9 | 5 | 7 |
31 Mar 21 | 1 | -9 | 4 | 7 |
31 Dec 20 | 1 | -8 | 4 | 7 |
30 Sep 20 | 1 | -7 | 4 | 6 |
30 Jun 20 | 1 | -6 | 4 | 5 |
31 Mar 20 | 1 | -6 | 4 | 6 |
31 Dec 19 | 1 | -7 | 4 | 6 |
30 Sep 19 | 1 | -6 | 4 | 6 |
30 Jun 19 | 1 | -6 | 3 | 6 |
31 Mar 19 | 1 | -6 | 4 | 5 |
31 Dec 18 | 1 | -6 | 4 | 5 |
30 Sep 18 | 1 | -6 | 4 | 5 |
30 Jun 18 | 1 | -6 | 4 | 5 |
31 Mar 18 | 1 | -4 | 3 | 4 |
31 Dec 17 | 1 | -2 | 3 | 4 |
30 Sep 17 | 1 | -3 | 3 | 4 |
30 Jun 17 | 1 | -4 | 3 | 4 |
31 Mar 17 | 1 | -4 | 3 | 4 |
31 Dec 16 | 1 | -4 | 3 | 4 |
30 Sep 16 | 1 | -4 | 3 | 3 |
30 Jun 16 | 1 | -4 | 3 | 3 |
31 Mar 16 | 1 | -4 | 3 | 2 |
31 Dec 15 | 1 | -3 | 4 | 2 |
30 Sep 15 | 1 | -4 | 4 | 1 |
30 Jun 15 | 1 | -4 | 5 | 1 |
31 Mar 15 | 1 | -4 | 5 | 1 |
31 Dec 14 | 1 | -5 | 4 | 1 |
30 Sep 14 | 1 | -3 | 4 | 1 |
30 Jun 14 | 1 | -2 | 3 | 1 |
31 Mar 14 | 1 | -2 | 2 | 1 |
31 Dec 13 | 1 | -1 | 2 | 0 |
30 Sep 13 | 1 | -1 | 2 | 0 |
30 Jun 13 | 1 | -1 | 2 | 0 |
Quality Earnings: OCC is currently unprofitable.
Growing Profit Margin: OCC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OCC is unprofitable, and losses have increased over the past 5 years at a rate of 5.1% per year.
Accelerating Growth: Unable to compare OCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.3%).
Return on Equity
High ROE: OCC has a negative Return on Equity (-340.71%), as it is currently unprofitable.